Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22023616 | 1.00 | ALDH1A1 (0.40) | ALDH1A1MAPTPNMTCYP2D6PRCP | |
| SCHEMBL14279490 | 1.00 | ALDH1A1 (0.40) | ALDH1A1MAPTPNMTCYP2D6PRCP | |
| SCHEMBL31097452 | 0.85 | DRD1 (0.38) | ALDH1A1MAPTPNMTCYP2D6CYP3A4 | |
| SCHEMBL13783357 | 0.81 | PRCP (0.56) | MAPTPRCPMEN1KMT2A | |
| SCHEMBL19223482 | 0.81 | PRCP (0.56) | MAPTPRCPMEN1KMT2A | |
| SCHEMBL21856320 | 0.80 | PNMT (0.52) | ALDH1A1MAPTPNMTCYP2D6CYP3A4 | |
| Hydrochloric Acid SCHEMBL28291673 | 0.78 | PNMT (0.50) | ALDH1A1MAPTPNMTCYP2D6CYP3A4 | |
| SCHEMBL29168653 | 0.76 | CHRNB2 (0.36) | CYP2D6DRD1 | |
| SCHEMBL15912353 | 0.74 | PNMT (0.34) | ALDH1A1MAPTPNMTCYP2D6MEN1 | |
| SCHEMBL873420 | 0.72 | ALDH1A1 (0.47) | ALDH1A1MAPTCYP2D6PRCPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-06-29 | — | — | US | disclosed |
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-06-29 | — | — | US | disclosed |
| US-11197864-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210078962-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-03-18 | — | — | US | disclosed |
| US-10844026-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200157069-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2020-05-21 | — | — | US | disclosed |
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | Biohaven Pharmaceutical Holding Company Limited (US) | 2019-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10357497-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, CYP3A5, UGT1A1 | ALDH1A1 45/4885MAPT 401/4885PNMT 2919/4885 |
| US-11197864-B2 | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis | CYP1A2, UGT1A1, SMN1; SMN2 | ALDH1A1 50/4885MAPT 564/4885PNMT 3089/4885 |
| US-20230202993-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | ALDH1A1 9/4885MAPT 423/4885PNMT 1759/4885 |
| US-20210078962-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | ALDH1A1 9/4885MAPT 423/4885PNMT 1759/4885 |
| US-10844026-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | ALDH1A1 9/4885MAPT 423/4885PNMT 1759/4885 |
| US-20200157069-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | APEH, UGT1A9, ALDH3A1 | ALDH1A1 9/4885MAPT 423/4885PNMT 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.